200 related articles for article (PubMed ID: 36871061)
1. Myelofibrosis-type megakaryocyte dysplasia (MTMD) as a distinct category of BCR::ABL-negative myeloproliferative neoplasms. Challenges and perspectives.
Barosi G; Rosti V; Gale RP
Leukemia; 2023 Apr; 37(4):725-727. PubMed ID: 36871061
[TBL] [Abstract][Full Text] [Related]
2. Clonal Megakaryocyte Dysplasia with Isolated Thrombocytosis Is a Distinct Myeloproliferative Neoplasm Phenotype.
Barosi G; Campanelli R; Massa M; Catarsi P; Carolei A; Abbà C; Villani L; Magrini U; Gregato G; Bertolini F; de Silvestri A; Gale RP; Rosti V
Acta Haematol; 2023; 146(1):14-25. PubMed ID: 36349787
[TBL] [Abstract][Full Text] [Related]
3. Novel findings of splenic extramedullary hematopoiesis during primary myelofibrosis, post-essential thrombocythemia, and post-polycythemia vera myelofibrosis.
Guy A; Bidet A; Ling C; Caumont C; Boureau L; Viallard JF; Parrens M
Virchows Arch; 2021 Oct; 479(4):755-764. PubMed ID: 33934231
[TBL] [Abstract][Full Text] [Related]
4. Proposal for revised diagnostic criteria of essential thrombocythemia and polycythemia vera by the Thrombocythemia Vera Study Group.
Michiels JJ; Juvonen E
Semin Thromb Hemost; 1997; 23(4):339-47. PubMed ID: 9263350
[TBL] [Abstract][Full Text] [Related]
5. [Megakaryocytopoiesis in myeloproliferative disorders].
Podolak-Dawidziak M
Acta Haematol Pol; 1992; 23(2 Suppl 1):19-22. PubMed ID: 1488868
[No Abstract] [Full Text] [Related]
6. Megakaryocytic morphology and clinical parameters in essential thrombocythemia, polycythemia vera, and primary myelofibrosis with and without JAK2 V617F.
Vytrva N; Stacher E; Regitnig P; Zinke-Cerwenka W; Hojas S; Hubmann E; Porwit A; Bjorkholm M; Hoefler G; Beham-Schmid C
Arch Pathol Lab Med; 2014 Sep; 138(9):1203-9. PubMed ID: 25171702
[TBL] [Abstract][Full Text] [Related]
7. Clinicopathological and molecular features of SF3B1-mutated myeloproliferative neoplasms.
Boiocchi L; Hasserjian RP; Pozdnyakova O; Wong WJ; Lennerz JK; Le LP; Dias-Santagata D; Iafrate AJ; Hobbs GS; Nardi V
Hum Pathol; 2019 Apr; 86():1-11. PubMed ID: 30594750
[TBL] [Abstract][Full Text] [Related]
8. GATA1 downregulation in prefibrotic and fibrotic stages of primary myelofibrosis and in the myelofibrotic progression of other myeloproliferative neoplasms.
Sangiorgio VFI; Nam A; Chen Z; Orazi A; Tam W
Leuk Res; 2021 Jan; 100():106495. PubMed ID: 33360878
[TBL] [Abstract][Full Text] [Related]
9. [Differential diagnosis of myeloproliferative neoplasms. Quantitative NF-E2 immunohistochemistry for differentiating between essential thrombocythemia and primary myelofibrosis].
Aumann K; Frey AV; May AM; Hauschke D; Kreutz C; Marx JP; Timmer J; Werner M; Pahl HL
Pathologe; 2013 Nov; 34 Suppl 2():201-9. PubMed ID: 24196613
[TBL] [Abstract][Full Text] [Related]
10. Analysis of megakaryocyte ploidy in patients with thrombocytosis.
Kanz L; Hollen C; Friese P; Burstein SA
Int J Cell Cloning; 1990 Jul; 8(4):299-306. PubMed ID: 2401806
[TBL] [Abstract][Full Text] [Related]
11. Pathogenetic mechanisms in chronic myeloproliferative disorders: polycythemia vera, essential thrombocythemia, agnogenic myeloid metaplasia, and chronic myelogenous leukemia.
Tefferi A
Semin Hematol; 1999 Jan; 36(1 Suppl 2):3-8. PubMed ID: 9930550
[TBL] [Abstract][Full Text] [Related]
12. Primary myelofibrosis is the most frequent myeloproliferative neoplasm associated with del(5q): clinicopathologic comparison of del(5q)-positive and -negative cases.
Santana-Davila R; Tefferi A; Holtan SG; Ketterling RP; Dewald GW; Knudson RA; Steensma DP; Chen D; Hoyer JD; Hanson CA
Leuk Res; 2008 Dec; 32(12):1927-30. PubMed ID: 18538839
[TBL] [Abstract][Full Text] [Related]
13. Disruption of the ASXL1 gene is frequent in primary, post-essential thrombocytosis and post-polycythemia vera myelofibrosis, but not essential thrombocytosis or polycythemia vera: analysis of molecular genetics and clinical phenotypes.
Stein BL; Williams DM; O'Keefe C; Rogers O; Ingersoll RG; Spivak JL; Verma A; Maciejewski JP; McDevitt MA; Moliterno AR
Haematologica; 2011 Oct; 96(10):1462-9. PubMed ID: 21712540
[TBL] [Abstract][Full Text] [Related]
14. Transcription factor 3 is dysregulated in megakaryocytes in myelofibrosis.
Collinson RJ; Wilson L; Boey D; Ng ZY; Mirzai B; Chuah HS; Howman R; Grove CS; Malherbe JAJ; Leahy MF; Linden MD; Fuller KA; Erber WN; Guo BB
Platelets; 2024 Dec; 35(1):2304173. PubMed ID: 38303515
[TBL] [Abstract][Full Text] [Related]
15. Clonal Megakaryocyte Dysplasia with Normal Blood Values Is a Distinct Myeloproliferative Neoplasm.
Barosi G; Rosti V; Massa M; Campanelli R; Villani L; Catarsi P; Carolei A; Abbà C; Lodigiani C; Primignani M; Gregato G; Bertolini F; Magrini U; Gale RP
Acta Haematol; 2022; 145(1):30-37. PubMed ID: 34280924
[TBL] [Abstract][Full Text] [Related]
16. Essential thrombocythemia vs. early/prefibrotic myelofibrosis: why does it matter.
Barosi G
Best Pract Res Clin Haematol; 2014 Jun; 27(2):129-40. PubMed ID: 25189724
[TBL] [Abstract][Full Text] [Related]
17. Clinical and pathological criteria for the diagnosis of essential thrombocythemia, polycythemia vera, and idiopathic myelofibrosis (agnogenic myeloid metaplasia).
Michiels JJ; Thiele J
Int J Hematol; 2002 Aug; 76(2):133-45. PubMed ID: 12215011
[TBL] [Abstract][Full Text] [Related]
18. Progression of Myeloproliferative Neoplasms (MPN): Diagnostic and Therapeutic Perspectives.
Baumeister J; Chatain N; Sofias AM; Lammers T; Koschmieder S
Cells; 2021 Dec; 10(12):. PubMed ID: 34944059
[TBL] [Abstract][Full Text] [Related]
19. Diagnosis, pathogenesis and treatment of the myeloproliferative disorders essential thrombocythemia, polycythemia vera and essential megakaryocytic granulocytic metaplasia and myelofibrosis.
Michiels JJ; Kutti J; Stark P; Bazzan M; Gugliotta L; Marchioli R; Griesshammer M; van Genderen PJ; Brière J; Kiladjian JJ; Barbui T; Finazzi G; Berlin NI; Pearson TC; Green AC; Fruchtmann SM; Silver RT; Hansmann E; Wehmeier A; Lengfelder E; Landolfi R; Kvasnicka HM; Hasselbalch H; Cervantes F; Thiele J
Neth J Med; 1999 Feb; 54(2):46-62. PubMed ID: 10079679
[TBL] [Abstract][Full Text] [Related]
20. The histopathology of chronic myeloproliferative diseases.
Georgii A; Buesche G; Kreft A
Baillieres Clin Haematol; 1998 Dec; 11(4):721-49. PubMed ID: 10640214
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
